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S U M M A R Y
Sexually acquired hepatitis C virus (HCV) infection remains a public health problem, with signiﬁcant
disease burden primarily in HIV-positive men who have sex with men (MSM). Over the past decades, the
epidemic of sexually transmitted HCV infection has continued to expand and the epidemiology of HCV in
HIV has changed signiﬁcantly. In the post-combination antiretroviral therapy era, sexual network
characteristics within the speciﬁc core group of MSM with increased sexual risk behaviours, including
serosorting on the basis of HIV-positive status and intense mucosally traumatic sexual practices, confer
increased HCV acquisition and transmission. This review summarizes the current epidemiology of
sexually acquired HCV infection and the clinical and immunological contexts of acute HCV infection, and
describes the biological, social, and behavioural factors that have facilitated permucosal transmission of
HCV in MSM. While the advent of direct-acting antivirals has improved treatment responses
signiﬁcantly, sexually transmitted HCV reinfections occur in a substantial proportion of HIV-positive
MSM following clearance of a primary infection. Effective strategies and preventive interventions that
are tailored to the MSM communities to facilitate the control of sexually acquired HCV infection cannot
be overemphasized.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen transmitted
primarily through parenteral exposures, including needle-sharing
among injection drug users (IDUs), transfusion of contaminated
blood products, and unsafe medical practices. Globally, a majority
of the disease burden of HCV falls on IDUs. Over the last two
decades, effective harm reduction practices have contributed to
the minimization of human immunodeﬁciency virus (HIV)
transmission, thereby concurrently reducing IDU exposure to
HCV. However, HCV infection in non-IDU men who have sex with
men (MSM) has increasingly been reported in the literature, a
pattern highlighting the importance of sexual transmission in the
epidemiological spread of HCV. From a biological standpoint, co-
infection with HIV may have a profound impact on the natural* Corresponding author. Tel.: +886 2 23123456 ext. 67552; fax: +886 2 23707772.
E-mail address: hcc0401@ntu.edu.tw (C.-C. Hung).
http://dx.doi.org/10.1016/j.ijid.2016.05.030
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).history of HCV disease, although combination antiretroviral
therapy (cART) is expected to reduce morbidity in HIV mono-
infection. The introduction of HCV treatment would likewise alter
the course of HCV epidemiology, but the increasing sexual
transmission of HCV, especially in the HIV-positive population,
may counterbalance the public health impacts of therapy. The
complex inter-relationship between sexual transmission of HCV
and HIV co-infection, as well as the potential impacts of HCV/HIV
therapies, requires a more comprehensive understanding of the
situation to inform effective clinical and public health responses in
the years to come.
In this article, the epidemiology of sexually transmitted HCV
infection in HIV-positive and HIV-negative MSM, the clinical and
immunological contexts of acute HCV infection, and the various
factors – biological, social, and behavioural – that may facilitate its
sexual transmission are reviewed. A MEDLINE search was
conducted to identify relevant studies published from January
1990 to March 2016; the search terms included ‘‘HCV’’, ‘‘HIV’’,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
D.P.C. Chan et al. / International Journal of Infectious Diseases 49 (2016) 47–5848‘‘MSM’’, ‘‘sexually acquired’’, ‘‘acute HCV’’, ‘‘epidemiology’’, ‘‘inci-
dence’’, ‘‘prevalence’’, ‘‘immunity’’, ‘‘sexual risk behaviour’’, ‘‘sexu-
ally transmitted infection’’, and ‘‘HCV treatment’’. Only articles and
conference abstracts written in English were included in this
review.
2. Epidemiology of sexually transmitted HCV infection
2.1. The uncommon occurrence of HCV as a sexually transmitted
infection
The epidemiological role of the sexual route in HCV transmis-
sion is controversial, and sexual contact is considered an inefﬁcient
mode of its spread. Several studies have reported low rates of
sexual transmission in HCV-serodiscordant heterosexual part-
ners.1–4 In cross-sectional studies from Europe, the USA, and
Southeast Asia, the prevalence rates of HCV among heterosexual
couples have ranged from 0% to 27%. Heterosexual transmission of
HCV, however, appears in only <5% when excluding partners with
known parenteral exposures.1 A recent study based on genotype
concordance has also supported the infrequent occurrence of
sexual transmission in monogamous heterosexual couples, with
HCV prevalence attributable to sexual contact estimated at 0.6%.4
2.2. Epidemic of sexually transmitted HCV infection in HIV-positive
MSM in Europe and the USA
Over the past two decades, there has been increasing evidence
of permucosal HCV transmission and the emergence of acute HCV
infection in HIV-positive MSM. The changing pattern of HCV
transmission was described in a study published in 2004, in which
the authors reported an increase in acute HCV infection among
HIV-positive MSM in London.5 In the majority of these cases, the
prevalence of drug injection was low and the main risk attributable
to HCV infection was unprotected anal sex. The emergence of HCV
as a sexually transmitted infection (STI) among HIV-positive MSM
has further been reported in case–control and cohort studies in
Switzerland,6 France,7 the Netherlands,8 England,9 Germany,10 the
USA,11 and Belgium.12 These reports coincided with the wide-
spread initiation of cART in the USA and Western Europe beginning
in the 1990s.
Epidemiological data on sexually acquired HCV in MSM have
focused on the rise in prevalent HCV infection with varied anti-HCV
positivity. In Northern Europe, among 777 HIV-positive MSM
enrolled in the STI clinic surveys in Amsterdam, the seroprevalence
of HCV increased from 5.6% in 1995 to 10.3% in 2010. Of the 91 HCV/
HIV co-infected MSM, only 11% reported drug injection, and the
epidemic of HCV was linked to such high-risk sexual behaviours as
unprotected anal sex and ﬁsting, and concurrent chlamydial
infection, conﬁrming permucosal transmission as the most likely
mode of HCV infection.13 In the UK, the prevalence of HCV infection
among HIV-positive MSM was low at 4.1% in 2002–2003,14 but a
rapid rise to 7.7% was observed by 2008.15 Outside Europe, high
rates of sexually transmitted HCV infection were also found in non-
IDU HIV-positive MSM in North America. In San Francisco, HCV
seroprevalence increased from 8.7% in 200416 to 12.3% in 2011.17
Although the incidence of HCV infection has been found to vary
across countries, there was a common increase in sexually
transmitted acute HCV infection in HIV-positive MSM starting in
the early 2000s. In Europe, the French PRIMO cohort study revealed
a higher HCV incidence rate of 0.83 per 100 person-years after
2003 compared with 0.12 per 100 person-years in the years before.7
A cohort study in Amsterdam showed a 10-fold increase in HCV
incidence in HIV-positive MSM between 1984 and 2003. A higher
incidence rate of 0.87 per 100 person-years was reported after
2000 compared with 0.08 in 1984–1999.8 In the UK, the incidence ofacute HCV seroconversions in HIV-positive MSM increased between
2004 and 2006, while the number of incident HCV infections
remained low between 1999 and 2003.18 Another cross-sectional
study among non-IDU MSM attending a sexual health clinic in
Brighton revealed an increasing incidence of HCV in HIV-positive
MSM, with incidence rates increasing from 1.11 per 100 person-
years in 2004 to 1.75 per 100 person-years in 2006.19 A cohort of
HIV-positive MSM at an HIV/STI clinic in Belgium showed HCV
incidence rates varying between 0.24 per 100 person-years in
2001 and 1.36 in 2011, with a peak rate of 2.93 per 100 person-years
in 2009.20,21 The incidence of HCV infection was also markedly
increased among HIV-positive MSM in Switzerland, with an 18-fold
increase observed between 1998 and 2011. In the Swiss Cohort
Study, an alarming HCV incidence rate of 4.09 per 100 person-years
was found in HIV-positive MSM in 2011, whereas the incidence rate
of HCV infection was 0.23 per 100 person-years in 1998.22 Across
Europe, the EuroSIDA Cohort reported an increase in HCV
seroconversions between 2002 and 2013, with the odds of acquiring
HCV infection among MSM increasing from 0.59% in 2002 to 2.23%
in 2013.23 Furthermore, in a collaborative multi-cohort study
examining incident HCV infection in MSM from 12 cohorts in
Europe and Canada, the HCV incidence rates rose from 0.09–0.22
per 100 person-years in 1990 to 2.34–5.11 in 2007, with the rapid
expansion of the HCV epidemic occurring after 2002.24 In North
America, Witt et al. revealed a higher HCV incidence in HIV-positive
MSM between the years 2005 and 2011 than between the years
2000 and 2004 in the USA.25
2.3. Epidemic of sexually transmitted HCV infection in HIV-positive
MSM outside Europe and the USA
Permucosal transmission of HCV is not conﬁned to Europe and
North America. Table 1 shows the HCV epidemic in HIV-positive
MSM with data reported from cross-sectional and cohort studies
performed in Europe, North America, and Asia.6–8,19–21,24–40 In a
review of 25 studies of acute HCV collected internationally, the
reported incidence rates ranged from 0 to 4.17 per 100 person-
years in HIV-positive MSM, with a pooled incidence rate of
0.608 per 100 person-years (95% conﬁdence interval (CI) 0.518–
0.699 per 100 person-years).41 A recent systematic review of
15 studies including Australia and Asia gave a similar pooled
incidence rate of 0.53 per 100 person-years (95% CI 0.49–0.58 per
100 person-years), with the incidence estimates ranging from 0 to
1.40 per 100 person-years.42 In Australia, the prospective studies of
acute HCV infection in HIV-positive MSM revealed high rates of
non-IDU sexually acquired HCV infection, with the prevalence
ranging from 50% to 56%.43,44 In a Taiwan cohort of 731 non-IDU
MSM, the incidence of recent HCV infection was reported to have
risen from 0 in 1994–2000 to 0.35 per 100 person-years in 2001–
2005, and further to 1.23 per 100 person-years in 2006–2010.38 In
a study of 753 HIV-positive MSM in Japan, 17 non-IDU MSM
seroconverted for HCV between 2005 and 2012, with the incidence
rate increasing from 0 in 2005–2006 to 2.02 per 100 person-years
in 2011–2012.39 Similarly, a study of 1311 HIV-positive MSM in
Hong Kong also revealed an increased incidence of HCV infection
from 0.13 per 100 person-years in 2002 to 0.19 per 100 person-
years in 2002–2007 and 0.47 per 100 person-years in 2008–
2013.40 The epidemic of sexually transmitted HCV infection is less
apparent in South America, where no cases of HCV infection were
found in a study of 162 HIV-positive MSM in Peru.45
2.4. Sexually transmitted HCV infection in HIV-negative MSM
While the majority of permucosal HCV transmission occurs in
HIV-positive MSM, sexual transmission of HCV appears to be very
limited in HIV-negative MSM (Figure 1). The data in Table 1 indicate
Table 1
Incidence of HCV among HIV-positive and HIV-negative MSM
Country City Year of
study
Study
design
MSM cases Total
person-years
HCV incidence per
100 person-years (95% CI)
Ref.
HIV-positive MSM
Europe
Switzerland 2000–2004 Cohort 414 (non-IDU MSM
with unsafe sex)
1157 (non-IDU MSM
with safe sex)
Not speciﬁed 0.70 (0.30–1.40)
0.20 (0.07–0.43)
Rauch et al., 20056
France 1996–2005 Cohort 327 1405 0.35 Ghosn et al., 20067
UK London 1999–2005 Cross-
sectional
308 1190 0.92 Turner et al., 200626
Netherlands Amsterdam 1984–2003 Cohort 491 4408 0.18 (0.08–0.36) van de Laar et al., 20078
UK Brighton 2000–2006 Cross-
sectional
Not speciﬁed 1361 1.18 (0.67–1.91) Richardson et al., 200819
UK London and
Brighton
2002–2006 Cross-
sectional
Not speciﬁed 42985 0.905 Giraudon et al., 200827
Spain Andalusia 2006 Cohort 727 (non-IDU MSM) Not speciﬁed 0.19 (0.13–0.47) Palacios et al., 200928
Belgium Antwerp 2001–2009 Cohort 5744 Not speciﬁed 1.20 Bottieau et al., 201020
Denmark Copenhagen 2006–2009 Cohort 871 Not speciﬁed 0.37 Barfod et al., 201129
International
(CASCADE
Collaboration)
1990–2007 Cohort 1354 Not speciﬁed 0.09 (0.005–1.52) in 1990
0.55 (0.27–1.30) in 1995
0.80 (0.60–1.88) in 2000
1.68 (1.03–2.74) in 2005
2.34 (0.82–6.69) in 2007
van der Helm et al., 201124
Belgium Antwerp 2001–2011 Cohort 418 (in 2001)
1105 (in 2011)
Not speciﬁed 0.24 in 2001
1.36 in 2011
Apers et al., 201321
Spain 2004–2011 Cohort 1416 3592 0.58 Sobrino-Vegas et al., 201430
Germany 1996–2012 Cohort 1784 6054 1.54 Jansen et al., 201531
North America
USA 1996–2008 Cohort 1830 (6% reported
injection drug use)
Not speciﬁed 0.40 (non-IDU MSM) Taylor et al., 201132
USA Multi-centre 1984–2011 Cohort 2041 Not speciﬁed 0.422 Witt et al., 201325
USA Boston 2008–2009 Cohort 379 1408 1.63 (0.97–2.30) Garg et al., 201333
USA New York 2000–2010 Cohort 41 303 (non-IDU MSM) 315 392 0.605 Breskin et al., 201534
Canada Ontario 2000–2010 Cohort 1534 9987 0.51 (0.39–0.67) Burchell et al., 201535
Asia
Australia Sydney 2005–2007 Cohort 159 238.1 0.00 (0.00–1.54a) Jin et al., 201036
Australia Melbourne 2002–2010 Cohort 581 (non-IDU MSM) 4018 0.60 (0.40–0.80) Gamage et al., 201137
Taiwan Taipei 1994–2010 Cohort 731 (non-IDU MSM) 3026 0.925 Sun et al., 201238
Japan Tokyo 2005–2012 Cohort 716 2146 0.792 Nishijima et al., 201439
China Hong Kong 1999–2013 Cohort 1311 6295 0.22(0.12–0.37) Lin et al., 201440
HIV-negative MSM
Europe
Netherlands Amsterdam 1984–2003 Cohort 1311 7808 0 (0.00–0.05) van de Laar et al., 20078
UK Brighton 2000–2006 Cross-
sectional
Not speciﬁed 3335 0.15 (0.05–0.35) Richardson et al., 200819
North America
USA San Francisco 1997–2000 Cohort 696 (non-IDU MSM) 577 0 (0.00–0.60) Hammer et al., 200346
Canada Montreal 1996–2001 Cohort 1053 (non-IDU MSM) 2610 0 (0.00–0.14) Alary et al., 200547
USA Multi-centre 1984–2011 Cohort 3269 Not speciﬁed 0.05 Witt et al., 201325
Asia
Australia Sydney 2001–2007 Cohort 1383 4412 0.11 (0.03–0.26)
(1 seroconverter reported
injection drug use)
Jin et al., 201036
China Nanjing Not speciﬁed Cohort 250 Not speciﬁed 0 (2.59–2.59) Hao et al., 201148
Taiwan Taipei 2006–2013 Cohort 1558 (non-IDU MSM) 3824 3.40 (1.55–5.25)
3.14 (0.06–6.23) in 2006–2009
2.47 (0.05–4.90) in 2010–2011
5.37 (0.66–10.08) in 2012–2013
Tsai et al., 201549
95% CI, 95% conﬁdence interval; IDU, injection drug users; HCV, hepatitis C virus; MSM, men who have sex with men.
a 97.5% CI.
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has remained low.8,19,25,36,46–49 Data from a systematic review
showed that HIV-negative MSM were at 4.1 times lower risk of
acute HCV infection than HIV-positive MSM. The pooled incidence
rate was estimated at 0.148 per 100 person-years (95% CI 0.075–
0.221 per 100 person-years), with HCV seroconversions ranging
from 0 to 0.81 per 100 person-years.41 Permucosal transmission of
acute HCV was unusual among HIV-negative MSM in the USA,46 the
Netherlands,8 Canada47 and China,48 where no cases of HCV
seroconversion were identiﬁed. Anti-HCV positivity was also less
common in HIV-negative MSM and only a few cases of sexuallyacquired HCV infection were reported in the Netherlands,13,50
Taiwan,49,51 Sweden,52 and Switzerland.53 In Taiwan, a 0.4%
seroprevalence of HCV was observed among HIV-negative
MSM.51 Consistent with this, based on 821 HIV-negative MSM
recruited at a gay health centre in Switzerland, a low HCV
seroprevalence (0.37%) was observed.53 In an Australian Trial in
Acute Hepatitis C (ATAHC) study, an HCV seroprevalence of 1.07%
was reported in the HIV-negative cohort, who were 10 times less
likely to acquire HCV infection than the HIV-positive MSM.36
Similarly, in a community survey carried out in London, the HCV
seroprevalence was 1.2% in HIV-negative MSM, which was seven
Figure 1. Overview of acute HCV infection in HIV-positive and HIV-negative MSM (HCV, hepatitis C virus; MSM, men who have sex with men; PY, person-years).
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few studies reporting increased incidence rates of sexually
transmitted HCV among non-IDU MSM with a negative or unknown
HIV status. In Brighton, incident HCV infection increased from 0 in
2000–2003 to 0.58 per 100 person-years in 2006.19 In Taiwan,
incident HCV infection among HIV-negative MSM seeking volun-
tary counselling and testing for HIV increased from 0.31 per
100 person-years during 2006–2009 to 0.54 per 100 person-years
during 2012–2013.49 In a recent retrospective study in the UK, there
were 44 HIV-negative MSM who seroconverted to HCV positivity
between 2010 and 2014.54
3. Molecular epidemiology of sexually transmitted HCV
infection
Molecular epidemiology studies are important for inferring the
transmission pathways of sexually acquired HCV and to speciﬁ-
cally look for clustering. Since the early 2000s, several clusters of
acute HCV infection have been reported in HIV-positive MSM in
association with high-risk sexual practices. Multiple monophyletic
HCV transmission clusters of HCV genotypes 1a, 1b, 3a, and 4d
within the MSM networks have been described in the
Netherlands,8,13,50,55,56 France,57,58 England,9 Spain,59 Germany,60
the USA11 and Asia.38,61–63 Reports from molecular studies have
shown that the MSM-speciﬁc HCV lineages and clusters, predomi-
nantly of HCV genotypes 1a and 4d in Europe, were separate from
IDU networks and phylogenetically distinct from HCV strains
circulating among IDUs. The shorter genetic distance of the HCVisolates suggested that sexually acquired virus circulating within
the HIV-positive population was of recent origin and had expanded
rapidly. An international molecular study of HCV sequences from
England, the Netherlands, France, Germany, and Australia uncov-
ered a large MSM-speciﬁc transmission network in HIV-positive
MSM. The evolutionary analysis indicated that the rapid expansion
of MSM-speciﬁc HCV lineages of genotypes 1a and 4d occurred in
Europe after 1996 following the introduction of cART, which might
have contributed to the spread of sexually transmitted HCV within
the social and sexual networks of HIV-positive MSM.64
Genetic clustering of sexually acquired HCV has shown
geographically distinct, differential patterns. Speciﬁcally, the
transmission network discovered in the European study supported
the clustering of HCV within European countries, as 74% of
European MSM were infected with an HCV lineage that co-
circulated in Europe.64 In contrast, acute HCV infection in HIV-
positive MSM in the USA and Asia showed limited overlap with the
international MSM-speciﬁc European network. In North America,
the incident HCV sequences from six major cities covering the east
and west coasts in the USA were genetically unrelated to the
European and Australian cases.65 Phylogenetic analysis demon-
strated extensive clustering of HCV genotype 1a within cities,
especially New York City and San Francisco, but minimal overlaps
between cities. In Asia, the molecular epidemiology of sexually
transmitted acute HCV infection also differed markedly. In
Australia, while no HCV genotype 4 was found, HCV genotypes
1a and 3a from HIV-positive MSM showed a strong link with those
circulating among local IDUs. In the ATAHC study, in which half of
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letic clusters identiﬁed in HIV-positive MSM were found to have
originated from and overlapped with IDU clusters, suggesting the
social mixing of the shared sexual and local IDU networks.61 In
Taiwan and Hong Kong, distinct MSM-speciﬁc transmission
networks of incident cases of HCV genotypes 1b38 and 3a63 were
recently described in HIV-positive MSM. In Hong Kong, a
monophyletic cluster has been circulating since 2011, which has
continued to expand, with no overlap with those in other cities/
countries.
4. Clinical contexts of acute HCV infection in HIV-positive
individuals
4.1. Diagnosis of newly acquired HCV infection
To study the epidemiology of sexually acquired HCV infection, a
common deﬁnition of acute infection is desirable, without which
the comparison of patterns in different places would not be
possible. The deﬁnition of acute or newly acquired HCV infection is,
however, quite arbitrary and has varied between studies.
Seroconversions for HCV within the previous 36 months,27,66
24 months,44 or 12 months38,64 have been used in different studies.
The European AIDS Treatment Network (NEAT) deﬁned acute HCV
infection as a positive HCV RNA or anti-HCV antibody result in a
documented anti-HCV-negative person in the previous
12 months.67 It has also been deﬁned as the ﬁrst detection of
anti-HCV antibody and clinical hepatitis diagnosed within the past
12 months,68 or a positive reverse transcription PCR (RT-PCR) test
for HCV RNA within 6 months of a preceding negative RT-PCR or
antibody test.69 Another study has referred to negative RT-PCR
within 8 months of the ﬁrst positive RT-PCR test.70 Routine and
regular screening of HCV in HIV-positive patients is the most
effective way of picking up sexually acquired HCV in MSM, as has
been reported in different studies.71,72
A presumptive diagnosis could also be made clinically during
early HCV infection for HIV-positive patients on regular monitor-
ing at HIV clinics. In one study, the majority (92.8%) of 111 HIV-
positive MSM with acute HCV infection were asymptomatic and
the diagnosis was made following investigations for abnormal
transaminases or screening for HIV and STIs, with only 7.2% icteric
on presentation.9 In a study of 43 HIV-positive patients with acute
HCV infection, 76% presented with elevated alanine aminotrans-
ferase (ALT) levels at the time of the ﬁrst positive RT-PCR at
baseline and 74% at 3 months.70 In contrast, delayed HCV
seroconversion was observed in HIV-positive individuals with
acute HCV infection, and this may result in delayed diagnosis and
treatment, and onward HCV transmission. At the time of the ﬁrst
positive HCV RT-PCR, only 25% of patients with acute HCV infection
had anti-HCV detected; this was 63% at 3 months, 87% at 6 months,
90% at 9 months, and 95% at 12 months.70 Compared with antibody
testing, an elevated ALT level was more sensitive (p = 0.017).
Virologically, three different patterns of viraemia were identi-
ﬁed in 112 HIV-positive patients with acute HCV infection on
examining their sequential plasma and peripheral blood mononu-
clear cell samples: (1) spontaneous clearance (15%), (2) progres-
sion towards chronicity with ﬂuctuating viraemia (37.5%), and (3)
progression towards chronicity with plateau viraemia (47.5%).69
Patients with spontaneous clearance were associated with an
initial increase followed by a rapid fall in plasma HCV RNA load,
leading to clearance at a median 108 days (95% CI 38–170 days).69
Spontaneous clearance was also associated with a rise in ALT and
bilirubin. The predictive factors of spontaneous clearance were the
maximum log10 drop in plasma HCV RNA load within 100 days,
peak bilirubin (>40 mmol/l, hazard ratio (HR) 5.04), peak ALT
(1000 IU/l, HR 2.62), and baseline CD4 count (650  106/l, HR2.66).69 In addition, the rate of decline of viraemia is key in
predicting the outcome, with the time to a 2.2-log10 drop being
signiﬁcantly shorter in patients with spontaneous clearance versus
ﬂuctuating viraemia (45 vs. 120 days, p = 0.01).
4.2. Impact of HIV infection on HCV infection
Compared with HIV-negative patients, HIV-positive patients
were found to be more likely to have viral persistence (95% vs. 62%)
during acute HCV infection,73 particularly those with lower CD4
counts74 and higher levels of HCV viraemia (65 187 IU/ml vs.
30 769 IU/ml).44 In the ATAHC study, a National Institutes of
Health-funded prospective cohort study, the clinical presentations
were, however, remarkably similar in HIV-positive and HIV-
negative patients, with approximately half (46–48%) experiencing
an acute viral illness and a similar mean maximum ALT level
(981 IU/ml vs. 937 IU/ml).44 However, in the German Network of
Competence for Hepatitis (Hep-Net) Study Group and the German
Hepatitis Group, HIV-positive patients had a lower median
maximum ALT level (261 IU/l (interquartile range (IQR) 92–499)
vs. 660 IU/l (IQR 363–1213)), presented less often with typical
symptoms or signs of hepatitis (32% vs. 59%), and had a longer
median time from the estimated infection to the ﬁrst occurrence of
symptoms (62 days (IQR 42–101) vs. 48 days (IQR 30–63)) than
HIV-negative patients.75 Such discrepancy in the observations of
clinical presentations between HIV-positive and HIV-negative
patients might result from the different characteristics of the HIV-
positive patients between the Australian and German studies.44,75
HIV status was at CDC stage A in 93% of the Australian group but
only 29% in the German group, and the median CD4 cell count was
614 and 473 (IQR 363–628) cells/ml, respectively. Furthermore, the
Australian group had more HIV-positive patients acquiring HCV
infection through injection drug use than the German group (44%
vs. 1%).44,75 Given a higher antigen exposure via injection drug
transmission, it is plausible that the mode of transmission might
affect the clinical presentations and the interval between the
estimated time of infection and the ﬁrst occurrence of clinical
symptoms.75
Additionally, HCV RNA was more frequently found in the semen
of HCV/HIV co-infected patients than in those with HCV
monoinfection (37.8% vs. 18.4%).76 This might further facilitate
HCV transmission through permucosal transmission in the HIV-
positive population. Furthermore, HIV infection accelerates
hepatic ﬁbrosis of chronic HCV infection,68 possibly through its
facilitation of HCV replication, immune dysregulation, and hepatic
ﬁbrogenesis and increased risk of hepatotoxicity arising from
antiretroviral therapy,77–80 leading to increases in liver-related
morbidity and mortality in HCV/HIV co-infected patients.81–83 In
the developed world, end-stage liver disease is now a leading cause
of death among HIV-infected individuals.82,83
4.3. Immunology of HIV and HCV co-infection
It has been demonstrated that a strong, broad, and sustained
HCV-speciﬁc cell-mediated response can control HCV infection.84–86
In HIV-negative patients, innate immune responses, particularly the
anti-HCV activity of natural killer (NK) cells, modulate the course of
acute HCV infection.87,88 Similar responses are also observed in HIV-
positive patients.89,90 The expression of CD27 has been shown to
deﬁne speciﬁc NK cell subsets, with CD27(+)CD56bright NK cells
displaying the strongest interferon gamma (IFN-g) secretion.91
Given the importance of IFN-g in the NK cell-mediated control of
HCV replication, a study demonstrated that CD27(+)CD56bright NK
cells have strong anti-HCV activity, and a high frequency of
CD27(+)CD56bright NK cells is associated with spontaneous clearance
of acute hepatitis C in HIV-positive patients.89 Furthermore,
D.P.C. Chan et al. / International Journal of Infectious Diseases 49 (2016) 47–5852CD3(+)CD56(+) NK-like T-cells, another subset of innate lympho-
cytes, share several characteristics with NK cells and are suggested
to modulate the outcome of acute HCV monoinfection.92 Likewise, in
HIV-positive patients, CD3(+)CD56(+) NK-like T-cells can effectively
block HCV replication but display an impaired IFN-g production.90
Additionally, in patients with acute HCV infection, higher viral
diversity plays an important role in the progression to chronicity,
while lower viral diversity is observed in those with HCV
clearance.93 Compared with HIV-negative patients with acute
HCV infection, a signiﬁcantly reduced cell-mediated response
against non-structural proteins and increased HCV genetic
diversity were observed in HIV-positive patients with acute HCV
infection,73,94 and this might contribute to the failure of early host
control of HCV in HIV-positive patients. Spontaneous clearance
occurred in HIV-positive patients with low viral diversity in the
presence of an early multi-speciﬁc T-cell response.69 Furthermore,
it was demonstrated that the CC genotype of a single-nucleotide
polymorphism 3 kb upstream of IL28B is the strongest and most
signiﬁcant genetic effect associated with natural clearance of HCV
infection,95 and a similar association was also observed in HCV/HIV
co-infected patients.96
5. Transmission risk of sexually acquired HCV infection
Although HCV infection is primarily associated with IDUs, most
of the MSM with acute or recent HCV infection have not reported
parenteral exposure. It appears that high-risk behaviours and
unprotected sex among certain networks of MSM are the major
risk factors for HCV transmission. A biological–behavioural–social
framework provides a better understanding of the potential risk
factors for sexually acquired HCV in MSM.
5.1. Biological factors: HIV and sexually transmitted infections
There is no evidence that HIV-positive men are more
susceptible to HCV infection due to immunological deﬁcits, or
that a more virulent HCV strain is isolated.67 Some HIV-positive
MSM may have higher seminal HCV RNA loads than HIV-negative
MSM,76 but this ﬁnding was not substantiated in another study.97
HIV-positive MSM are prone to chronic gastrointestinal inﬂamma-
tion, which may weaken the mucosal immune system and
facilitate HCV transmission.98 Multiple studies have indicated
the association of HCV with STIs.5,8,50 Some ulcerative STIs, such as
syphilis and lymphogranuloma venereum, may increase the risk of
HCV infection by creating a portal of entry through the mucosal
barrier.8,99 Observational studies showed that the emergence of
HCV infection among MSM coincided with epidemics of other
STIs.8 Past history of STI may also be a predictor of HCV
serocoversion.50,100 Since HIV, HCV, and STIs are risk factors for
each other, their syndemic relationships are making the HIV/HCV/
STIs co-epidemics more complicated.
5.2. Behavioural factors: unprotected anal sex, serosorting, and
chemsex
Although the mechanisms of permucosal transmission of HCV
remain uncharacterized, the association between HCV infection
and unprotected sex is well-demonstrated.8,11,64,99 Unprotected
anal intercourse is a key factor for acquiring HIV, HCV, and other
STIs. Regardless of HIV status, some men may engage in certain
‘esoteric’ sexual practices that can indirectly place them at a higher
risk of blood-borne virus infection. Examples of these practices are
anal eroticism, use of sex toys, ﬁsting (inserting hand or forearm
into rectum), bondage/dominance/sadomasochism (BDSM), and
group sex. Although many of these practices do not pose a speciﬁc
risk for HCV/HIV transmission, the results of case–control studiesin the UK,9 Germany,101 and Australia102 suggest that they could be
important predictors of the spread of blood-borne viruses within
the MSM community. Certain esoteric practices, like receptive
ﬁsting and enema use before anal sex, may induce anal or rectal
mucosal trauma that facilitates viral transmission.101,103 Further-
more, men who practise esoteric sex are more likely to be ‘sexual
sensation seekers’ who may at the same time engage in a wider
range of risky practices and drug use.102
Some HIV-positive MSM prefer to have sex with partners of the
same HIV status, a practice referred to as serosorting. While
serosorting may be considered as a ‘harm reduction’ strategy for
reducing HIV transmission, several studies have shown a high
prevalence of unprotected sex among serosorted sex.104–106 After
the introduction of cART, the general concerns of MSM about
having unsafe sex might have reduced.107 Indeed, the increase in
HCV infections among HIV-positive MSM appears to have
coincided with the introduction of cART in 1996.50 It is possible
that some ‘core groups’ of sexually active MSM, both HIV-positive
and HIV-negative, have continued to practise unprotected sex in
the post-cART era. STIs, including HIV and HCV, could spread
efﬁciently among networks of MSM associated with these core
groups.
Studies in the UK have recently reported a subculture of
recreational drug use before and/or during sex to enhance sexual
pleasure in the MSM community.108–110 This sexualized drug use,
sometimes referred to as ‘chemsex’ in the UK108 or ‘party and play’
in North America and Australia,111 involves the intentional
combination of sex with the use of psychoactive drugs including
crystal methamphetamine, mephedrone, and gamma-hydroxybu-
tyric acid (GHB)/gamma-butyrolactone (GBL). On the one hand, a
small proportion of men may administer the drugs by injection,
which directly poses a risk for HCV infection if needle-sharing
takes place;112 on the other hand, chemsex has been associated
with high-risk sexual behaviour and STIs. It is noteworthy that
chemsex drug use at sex parties, including injecting and needle-
sharing, has become more common in MSM. Findings from studies
in Australia,113 the USA,114 and London115 have revealed that
unprotected anal sex and sex with multiple partners are frequently
reported among MSM engaging in chemsex. These increased
sexual risk behaviours, coupled with potential anal or rectal
trauma resulting from longer and intense sexual encounters under
the inﬂuence of drugs, could facilitate STI transmission among
MSM. In the UK, sexual transmission of Shigella ﬂexneri 3a has been
linked with chemsex drug use in MSM in London.116 Similarly, a
case–control study in the Netherlands also revealed the association
between chemsex drug use (GHB/GBL) and sexually transmitted
acute HCV infection among HIV-positive MSM.117
5.3. Social factors: globalization and the advance in communication
technology
In the past few decades, the convenience of international travel
and the emergence of communication channels have provided new
opportunities for sexual exchanges that transcend social and
geographical boundaries. Many studies have reported that
unprotected sex and other high-risk behaviours are prevalent
among MSM who seek sex from the Internet and geosocial
applications.118–120Advances in communication technology have
apparently provided a convenient platform for HIV-positive MSM
to search for serosorted partners.121,122 Phylogenetic studies have
revealed that HCV transmission networks are national as well as
international,8,64 and the MSM-speciﬁc clusters identiﬁed in HCV/
HIV co-infected MSM recruited from Europe were characterized by
country mixing.64 Speciﬁcally, these transmission networks were
very likely to be sexual, on the assumption that most of the
study participants did not report any parenteral exposure.64
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6. Antiviral treatment for HCV infection among HIV-positive
patients
The increasing transmission of HCV in MSM emerged at the same
time as the evolution of new and potentially more effective
treatment regimens for HCV infection. Conventional treatment with
pegylated interferon (PEG-IFN) and ribavirin (RBV) among HIV-
positive patients gave a sustained virological response (SVR) rate of
47–91% for acute HCV infection,44,123,124while in those with chronic
HCV infection the SVR rate was only 27–40%.125 With the approval
of HCV direct-acting antivirals (DAAs) by the Food and Drug
Administration (FDA) in 2011, the outcome in HCV/HIV co-infected
patients has shown signiﬁcant improvement. Trials involving oral
interferon-free anti-HCV treatments in HCV/HIV co-infected
patients are summarized in Table 2.126–133 The PHOTO-1 study
reported that the SVR12 (deﬁned as an HCV RNA load <25 copies/ml
12 weeks after cessation of HCV therapy) of HCV treatment-naı¨ve
HIV-positive patients treated with sofosbuvir (SOF) and RBV for
12 week was 88% in those with HCV genotype 2 infection and 67% in
those with HCV genotype 3 infection.126 For HCV treatment-naı¨ve
HIV-positive patients with genotype 1 infection and treatment-
experienced HIV-positive patients with genotypes 2 and 3 infection,
the same regimen for 24 weeks led to SVR12 of 76.3% and 92.7%,Table 2
Summary of oral interferon-free anti-HCV treatments in HCV/HIV co-infected patients
Trial name
Regimen
Number
of patients
Treatment duration 
PHOTO-1
Sofosbuvir/ribavirin
224 Tx-naı¨ve GT 1/
Tx-experienced GT 2 and 3:
24 weeks (70%)
Tx-naı¨ve GT 2 and 3:
12 weeks (30%)
PHOTO-2
Sofosbuvir/ribavirin
274 GT 1, 3, 4/
Tx-experienced GT 2:
24 weeks (93%)
Tx-naı¨ve GT 2: 12 weeks (7%)
C-WORTHY
Grazoprevir/elbasvir  ribavirin
59 12 weeks
With ribavirin (49%)
Without ribavirin (51%)
C-EDGE
Grazoprevir/elbasvir
218 12 weeks (100%) 
ERADICATE
Ledipasvir/sofosbuvir
50 12 weeks
Not on ART (26%)
On ART (74%)
ION-4
Ledipasvir/sofosbuvir
335 12 weeks (100%) 
ALLY-2
Daclatasvir/sofosbuvir
203 12 weeks (75%)
8 weeks (25%)
TURQUOISE-I
Ombitasvir/paritaprevir/
ritonavir/dasabuvir/ribavirin
63 24 weeks (49%)
12 weeks (51%)
ART, antiretroviral therapy; GT, genotype; HCV, hepatitis C virus; NA, not available; SV
treatment.respectively.126 PHOTON-2 expanded the results of PHOTON-1 by
including patients with HCV genotype 4 infection and veriﬁed the
beneﬁt associated with a longer treatment duration for patients
with HCV genotype 3 infection, irrespective of previous treat-
ment.127 With the same regimen, SVR12 was 85% in HCV/HIV co-
infected patients with genotype 1, 88% in genotype 2, 89% in
genotype 3, and 84% in genotype 4.127 The study concluded that SOF
and RBV could lead to high rates of SVR after 12 weeks of treatment
in treatment-naı¨ve and treatment-experienced patients co-infected
with HIV and HCV genotypes 1–4.127
More recently, oral regimens of DAAs that combine more than
one potent antiviral agent have appeared to offer enhanced rates of
response over those seen with a single DAA plus RBV with or
without PEG-IFN.134 Both C-WORTHY and C-EDGE evaluated the
efﬁcacy of grazoprevir (GZR)/elbasvir (EBR) in HCV/HIV co-infected
patients.128,129 C-WORTHY reported SVR12 rates of 97% and 87% in
HCV treatment-naı¨ve HIV-positive patients with HCV genotype
1 infection treated with GZR/EBR with or without RBV, respective-
ly.128 The C-EDGE co-infection study demonstrated that this
regimen for 12 weeks for HCV treatment-naı¨ve HIV-positive
patients, with or without cirrhosis, with chronic HCV genotype 1,
4, or 6 infection, led to an overall SVR12 rate of 96% (210/
218).129Additionally, ERADICATE and ION-4 assessed the efﬁcacy of
ledipasvir (LDV)/SOF for 12 weeks, and the overall SVR12 rate was
98% and 96%, respectively.130,131 The combination of daclatasvir
(DCV) and SOF with limited pharmacokinetic interactions withGenotype Study populations (%) SVR12 Ref.
1a (27%)
1b (7%)
2 (15%)
3 (18%)
Tx-naı¨ve (82%)
Tx-experienced (18%)
Liver cirrhosis (7%)
Black (16%)
Tx-naı¨ve
GT 1: 76%
GT 2: 88%
GT 3: 67%
Tx-experienced
GT 2: 92%
GT 3: 94%
126
1 (41%)
2 (9%)
3 (39%)
4 (11%)
Tx-naı¨ve (80%)
Tx-experienced (20%)
Liver cirrhosis (20%)
Black (1%)
GT 1: 85%
GT 2: 88%
GT 3: 89%
GT 4: 84%
127
1a (78%)
1b (22%)
Tx-naı¨ve (100%)
Tx-experienced (0%)
Liver cirrhosis (0%)
Black (NA)
With ribavirin: 97%
Without ribavirin: 87%
128
1a (66%)
1b (20%)
4 (13%)
6 (1%)
Tx-naı¨ve (100%)
Tx-experienced (0%)
Liver cirrhosis (16%)
Black (17%)
GT 1a: 94.4%
GT 1b: 95.5%
GT 4: 96.4%
129
1a (78%)
1b (20%)
Tx-naı¨ve (100%)
Tx-experienced (0%)
Liver cirrhosis (0%)
Black (84%)
GT 1
Not on ART: 100%
On ART: 97%
130
1a (75%)
1b (23%)
4 (2%)
Tx-naı¨ve (45%)
Tx-experienced (55%)
Liver cirrhosis (20%)
Black (34%)
GT 1a: 96%
GT 1b: 96%
GT 4: 100%
131
1a (68%)
1b (14%)
2 (9%)
3 (6%)
4 (1%)
Tx-naı¨ve (74%)
Tx-experienced (26%)
Liver cirrhosis (14%)
Black (34%)
Tx-naı¨ve
GT 1, 12 weeks: 96.4%
GT 1, 8 weeks: 75.6%
GT 2–4, 12 weeks: 100%
GT 2–4, 8 weeks: 78%
Tx-experienced
GT 1, 12 weeks: 100%
GT 2–4, 12 weeks: 98.1%
132
1 (100%) Tx-naı¨ve (67%)
Tx-experienced (33%)
Liver cirrhosis (19%)
Black (24%)
GT 1
12 weeks: 94%
24 weeks: 91%
133
R12, sustained virological response 12 weeks after cessation of HCV therapy; Tx,
D.P.C. Chan et al. / International Journal of Infectious Diseases 49 (2016) 47–5854antiretroviral drugs achieved SVR12 across all genotypes of 97% in
those treated for 12 weeks and 76% in those treated for 8 weeks.132
Furthermore, treatment with an all-oral three-DAA regimen of
ombitasvir (OMV), paritaprevir (PRV) (co-dose with ritonavir (PRV/
r)), and dasabuvir (DSV) plus RBV for 12 or 24 weeks in TURQUOISE-I
led to SVR12 rates of 94% (29/31) and 91% (29/32) in patients
receiving 12 and 24 weeks of treatment, respectively.133 These
SVR12 rates were consistent with those of the trials using the same
regimens in the HCV monoinfected population.135Overall, it appears
that effective treatment of HCV is becoming more achievable for HIV
patients. Nevertheless, drug–drug interactions should be evaluated
carefully to avoid potential harm,136 and that cost is another issue
that would need to be addressed.
Treatment for acute HCV infection is suggested for HIV-positive
patients without a decrease of 2 log10 in HCV RNA at 4 weeks
compared with the initial HCV-RNA and for those with persistent
serum HCV RNA at 12 weeks after diagnosis of acute HCV
infection.67 PEG-IFN and RBV are recommended as the treatment
agents given the absence of randomized, controlled data on the use
of DAAs in the setting of acute HCV infection in HIV-positive
patients.137 Nevertheless, preliminary results of studies investigat-
ing the treatment of acute HCV infection in HIV-positive patients
with all-oral DAA agents are available, and are summarized in
Table 3.138–143 The numbers of cases included in these studies were
small (12–26 cases), and SVR12 varied signiﬁcantly among studies,
ranging from 21% to 100%. Such differences might result from
different deﬁnitions of acute HCV infection and variable durations
from the ﬁrst evidence of HCV infection to the initiation of HCV
treatment, which might include patients with early chronic HCV
infection with lower overall SVR rates, variable treatment regimens
(SOF/RBV, SOF/LDV, and SOF/SIM) and duration (4–12 weeks), and
different virus (HCV RNA load) or host factors (type of IL28B).
Nevertheless, some factors associated with treatment outcomes are
observed. In SWIFT-C, RBV concentrations were 52% higher in those
who achieved SVR than in those who did not (p = 0.001).139 In
another study, all patients who relapsed had a high HCV RNA load
between 7.0 and 7.2 log10 IU/ml, suggesting that a treatment
duration longer than 12 weeks or waiting for HCV RNA load drops
should be considered.138 Lastly, no new NS5A or NS5B resistance-
associated variants were observed at relapse and no drug
discontinuation due to an adverse reaction occurred.138
It is worth mentioning that subsequent recurrence of HCV
infection after achieving SVR, either from late relapse or
reinfection, compromises the beneﬁcial effects of SVR after early
treatment. A systematic review and meta-analysis showed that
HCV/HIV co-infected patients had the highest 5-year recurrence
risk of 15.02% compared to HCV monoinfected ‘high-risk’ patients
(IDUs or prisoners) and HCV-monoinfected ‘low-risk’ patients
(10.67% and 0.95%, respectively).144 The study concluded that
despite the low probability of late relapse, reinfection in high-risk
groups, such as IDUs, prisoners, and HIV-positive MSM, remainsTable 3
Summary of studies investigating the treatment of acute HCV in HIV-positive patients
Study name Oral
agents
Duration Number
of patients
Duration from HCV
diagnosis to treatment
HCV geno
(n)
NA SOF/LDV 6 weeks 26 NA 1a (18), 4
SWIFT-C
(ACTG 5327)
SOF/RBV 12 weeks 17 20 (IQR 17.3– 21.6)
weeks
1a (11), 1
DARE-CII SOF/RBV 6 weeks 14 NA NA 
NA SOF/RBV 12 weeks 12 22 (IQR 15–34) weeks 1a (10), 1
SLAM C SOF/LDV 4 weeks 14 NA 1a (7), 1b
SOF/SIM 8 weeks 15 NA 1a (7), 1b
HCV, hepatitis C virus; IQR, interquartile range; LDV, ledipasvir; NA, not available; RBV, r
virological response 12 weeks after cessation of HCV therapy.
a One dropped and one lost to follow-up.challenging to the successful control of HCV transmission.
Strategies to minimize the risk of reinfection in high-risk groups
need to be intensiﬁed, along with current effective anti-HCV
treatment, to curb ongoing HCV transmission.144
7. Gaps in preventing HCV transmission through sex
Sexual transmission of HCV is an added dimension to HCV and
HIV epidemiology, although this has, to date, predominantly
affected the MSM population. Gaps in our understanding of the
situation are addressed in this section. It appears that few studies
have speciﬁcally looked at how social and structural factors may
facilitate HCV transmission. There is also a scarcity of data on the
needs for HCV information and support from the MSM perspective,
and on evaluating the efﬁcacy of HCV health interventions.
7.1. Suboptimal HCV screening programmes
Effective screening has been shown to be the best means of
promptly identifying acutely or recently acquired HCV infections
in MSM. Guidelines in Europe, the USA, and Australia have
recommended that all newly diagnosed HIV individuals undergo
serological screening for HCV antibody at initial evaluation and
then annually.67,145,146 In the USA, however, signiﬁcant practice
variation among different clinical settings has been reported.147
MSM have been shown to appear less likely than IDUs to have ever
undergone HCV screening even under the current testing guide-
lines, and only half with ALT elevation had been followed by a
diagnostic HCV antibody testing within the subsequent
12 months.72 There are currently no universally agreed diagnostic
criteria for acute HCV infection, nor is there consensus on the role
of ALT screening.147 While the NEAT has recommended ALT
screening 6-monthly for HIV-positive MSM with risk behaviours,
the US Centers for Disease Control and Prevention (CDC) have
taken on a more cautious approach without speciﬁc recommen-
dation on the frequency of testing.67,145 Whether HCV screening
should be expanded to HIV-negative MSM remains a debatable
issue and there is no consensus guideline to this day. Evidence is
accumulating that HIV-negative MSM may also be at risk of HCV
infection,148 but only a small number have so far been screened for
HCV.54Although current evidence is insufﬁcient to warrant routine
HCV screening for HIV-negative MSM, a systematic review
concluded that their screening could be an effective public health
measure.41 In the absence of a cost-effectiveness analysis on HCV
testing in the MSM population, the design of practicable HCV
screening would remain a challenge.
7.2. Information on HCV for MSM
The lack of HCV knowledge among MSM has been described
previously.149–152 An online study reported low awareness of HCV with oral direct-acting antivirals
type HCV viral load, IU/ml Type of IL28B (n) SVR12% (n/N) Ref.
 (8) Mean 5.4 log10
(range <15–7.3 log10)
CC (12) 77 (20/26) 138
b (2) Mean 5.63 log10
(SD 1.76 log10)
CC (4), CT (10), TT (3) 59 (10/17) 139, 140
NA NA 21 (3/14) 141
b (2) Median 4.47 log10 CC (7), CT (5) 92 (11/12) 142
 (7) Mean 1200 k CC (4), CT (4), TT (6) 100 (14/14) 143
 (8) Mean 1600 k CC (3), CT (3), TT (9) 100 (13/13a)
ibavirin; SD, standard deviation; SIM, simeprevir; SOF, sofosbuvir; SVR12, sustained
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with fewer than half ever having received relevant information.149
A study in Amsterdam showed that MSM had limited knowledge of
HCV infection, especially on the seriousness of its potential
complications.150 In Australia, many MSM were unaware of the
linkage between HIV and HCV, and around 80% of the respondents
in one study expressed unmet needs of HCV information.151
Another recent Australian study reported discrepancy between
HIV-positive and HIV-negative/untested MSM regarding their
knowledge and attitudes towards IDUs and people with HCV.152
Compared to HIV-negative/untested men, HIV-positive men were
more likely to engage in HCV risk behaviours, but at the same time
they had better knowledge and a more positive attitude towards
IDUs and those with HCV.152 The observations concurred with
study results in Amsterdam and London, which demonstrated that
MSM who practiced risky sexual behaviours were more likely to be
aware of HCV than men at lower risk.150,153 In the absence of
tailored HCV information, MSM in the community might have a
false perception of their HCV risk and be unable to protect
themselves from the infection.151
7.3. Social stigma
Stigma and discrimination may contribute indirectly but
signiﬁcantly to the growth of the HIV/HCV epidemic. In many
societies, HIV and HCV infection are stigmatized because of their
association with ‘deviant’ behaviours, such as man-to-man sex and
drug injection.154,155 Strong evidence has shown that stigma and
discrimination could discourage accessibility to health messages
and services.156–159 Furthermore, the effects of stigma can aggregate
if an individual possesses more than one discredited characteristic.
MSM experience a double- or even triple-stigma related to being
associated with HIV and/or HCV infection and the reinforcement of
pre-existing stigmas.155 Even among HIV-serosorted sexual rela-
tionships, HCV/HIV co-infected MSM may not disclose their HCV
status to their HIV-positive sex partners because of the fear of being
stigmatized or discriminated against. Social stigma could hinder the
design and implementation of harm reduction programmes. Despite
the abundance of evidence on the efﬁcacy of harm reduction,
interventions like needle exchange, condom distribution, and safe
sex messages can attract serious criticism because of the stigma
attached to these behaviours.154,155 Stigma and discrimination can
drive the spread of diseases by pushing people underground, as well
as by impeding health interventions.
8. Conclusions
Epidemiological studies have shown that the emerging
epidemic of sexually transmitted HCV is currently limited largely
to HIV-positive MSM. Signiﬁcant clustering of HCV infections has
been demonstrated, as evidenced in molecular analyses, while the
rise in incidence has been moderate. To date, most of the
epidemiologic studies on sexually transmitted HCV infection have
been reported in the Western World, although a similar pattern is
beginning to be seen in the rest of the world, including Asian
countries. The sources of some of these outbreaks have been linked
with the local IDU communities, while others have appeared to be
concentrated in serosorting HIV-positive MSM. Their association
with intense sexual activities under the inﬂuence of substance
abuse, e.g., chemsex, has been observed in some of the outbreaks.
Another characteristic of sexually acquired HCV is the concurrent
emergence of STI outbreaks in the same community, such that
there are temporospatial overlaps between multiple infections.
Clinically, HCV infections in HIV-positive MSM are largely similar
to those occurring outside the HIV-positive population, although
progression to chronicity and multiple comorbidities are commonfollowing acute HCV infection in those living with HIV. Despite
remarkable progress in the treatment of HCV infection with the
achievement of high SVR rates irrespective of one’s HIV status,
successful treatment gives no protection against reinfection, which
has been shown to occur in a substantial proportion of the HIV-
positive MSM subsequent to effective HCV therapy.
The rising burden of sexually acquired HCV infection remains
both a clinical and public health challenge. Limited research has so
far been conducted in characterizing the HCV transmission
networks and their association with social, behavioural, and
structural factors in society. While the route of HCV transmission is
well known, awareness of MSM at risk of infection remains low.
Targeted HCV antibody testing interventions are effective in
promoting early diagnosis and increasing treatment uptake, but
these efforts cannot replace innovations in primary prevention to
reduce the HCV burden in the high-risk communities. Operational
research is urgently needed to translate new knowledge into
effective evidence-based interventions, which should then be
organized systematically and integrated with STI and HIV
prevention in programmes supporting linkage to care coupled
with active involvement of the community. With the increasing
coverage of cART, it is possible that the size of the vulnerable
population, i.e. HIV-positive MSM, could be rising, and we are only
seeing the beginning of the new HCV epidemic.
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